JP2021535163A5 - - Google Patents

Info

Publication number
JP2021535163A5
JP2021535163A5 JP2021511544A JP2021511544A JP2021535163A5 JP 2021535163 A5 JP2021535163 A5 JP 2021535163A5 JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021511544 A JP2021511544 A JP 2021511544A JP 2021535163 A5 JP2021535163 A5 JP 2021535163A5
Authority
JP
Japan
Prior art keywords
composition
composition according
taurinamide
taurartum
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021511544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535163A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/048592 external-priority patent/WO2020047113A1/en
Publication of JP2021535163A publication Critical patent/JP2021535163A/ja
Publication of JP2021535163A5 publication Critical patent/JP2021535163A5/ja
Priority to JP2024154822A priority Critical patent/JP2024170590A/ja
Pending legal-status Critical Current

Links

JP2021511544A 2018-08-28 2019-08-28 タウロリジン加水分解産物による神経芽細胞腫治療 Pending JP2021535163A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024154822A JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862723618P 2018-08-28 2018-08-28
US62/723,618 2018-08-28
PCT/US2019/048592 WO2020047113A1 (en) 2018-08-28 2019-08-28 Neuroblastoma treatment with taurolidine hydrolysis products

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024154822A Division JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Publications (2)

Publication Number Publication Date
JP2021535163A JP2021535163A (ja) 2021-12-16
JP2021535163A5 true JP2021535163A5 (https=) 2022-08-30

Family

ID=69645349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021511544A Pending JP2021535163A (ja) 2018-08-28 2019-08-28 タウロリジン加水分解産物による神経芽細胞腫治療
JP2024154822A Pending JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024154822A Pending JP2024170590A (ja) 2018-08-28 2024-09-09 タウロリジン加水分解産物による神経芽細胞腫治療

Country Status (7)

Country Link
EP (1) EP3843746A4 (https=)
JP (2) JP2021535163A (https=)
KR (1) KR20210050544A (https=)
CN (1) CN113347976A (https=)
AU (1) AU2019330954B2 (https=)
CA (1) CA3111057A1 (https=)
WO (1) WO2020047113A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3843747A4 (en) * 2018-08-31 2022-12-28 CorMedix Inc. TAUROLIDINE TREATMENT FOR MYC-EXPRESSING TUMORS IN MAMMALIAN BODY
US20220313702A1 (en) * 2019-05-22 2022-10-06 Geistlich Pharma Ag Oxathiazin compounds for inhibiting gapdh
CN116769723B (zh) * 2023-08-09 2023-11-03 山东省成体细胞产业技术研究院有限公司 一种gd2嵌合抗原受体修饰的t细胞及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
US20050096314A1 (en) * 2001-04-03 2005-05-05 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Treatment of cancers with methylol-containing compounds and at least one electrolyte
CN100519525C (zh) * 1999-12-06 2009-07-29 葛兰素集团有限公司 芳香砜类及其医疗用途
EP1248625A2 (en) * 1999-12-06 2002-10-16 Rhode Island Hospital Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
CA2363973C (en) * 2000-11-28 2009-03-10 Ed. Geistlich Sohne Ag Fur Chemische Industrie Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
ATE354380T1 (de) * 2003-02-03 2007-03-15 Polaschegg Hans-Dietrich Dr Te Zusammensetzung zur prävention von infektionen durch subkutane prothesen
WO2005115357A2 (en) * 2004-05-14 2005-12-08 Hans-Dietrich Polaschegg Taurolidine formulations and delivery
EP1976531B1 (en) * 2006-01-06 2011-11-09 Ed. Geistlich Söhne AG für Chemische Industrie Irradiated compositions and treatment of cancers with radiation in combination with taurolidine and/or taurultam
CA2801309C (en) * 2010-06-01 2018-07-17 Geistlich Pharma Ag Methods and compositions for oral pharmaceutical therapy
MX2014011843A (es) * 2012-03-30 2014-12-10 Novartis Ag Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
JP7614714B2 (ja) * 2016-01-11 2025-01-16 コーメディクス・インコーポレーテッド 神経芽細胞腫及びその他のがん治療のための治療ナノ粒子

Similar Documents

Publication Publication Date Title
EP4631571A3 (en) Combination of dextromethorphan and bupropion for treating depression
FI3426285T3 (fi) Pegyloidun urikaasin formulaatioita ja annoksia
WO2003039436A3 (es) Composiciones farmaceuticas que contienen oxibutinina
JP2004508404A5 (https=)
JP2002532392A5 (https=)
DK1453487T3 (da) Farmaceutisk doseringsform med flere belægninger for reduceret virkning af belægningsbrud
RU96122884A (ru) Способ лечения рака у человека
JP2020516646A5 (https=)
JP2021535163A5 (https=)
WO2021062282A1 (en) Combination therapy with cgrp antagonists
KR20140025314A (ko) 복합 조성물
US20030008875A1 (en) Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2005126819A (ru) Усовершенствованное лечение опухолей
JP2008540364A5 (https=)
JP2025148449A5 (https=)
JP2016505050A5 (https=)
JP2019506397A5 (https=)
FI3359572T3 (fi) Menetelmä multippeliskleroosin hoitamiseksi
Galanello Iron chelation: new therapies
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2019509309A5 (https=)
FI4255563T3 (fi) 5’-o-fenyyliasetyyliuridiini ja terapeuttinen käyttö
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
CN114073698B (zh) 一种止痛止痒药物组合物及其应用方法